Silent cerebral lesions and cognitive function after pulmonary vein isolation with an irrigated gold-tip catheter: REDUCE-TE Pilot study

Boris Schmidt, Gábor Széplaki, Bela Merkely, Josef Kautzner, Vincent van Driel, Felix Bourier, Malte Kuniss, Alan Bulava, Georg Nölker, Muchtiar Khan, Thorsten Lewalter, Norbert Klein, Beate Wenzel, Julian Kr Chun, Dipen Shah, Boris Schmidt, Gábor Széplaki, Bela Merkely, Josef Kautzner, Vincent van Driel, Felix Bourier, Malte Kuniss, Alan Bulava, Georg Nölker, Muchtiar Khan, Thorsten Lewalter, Norbert Klein, Beate Wenzel, Julian Kr Chun, Dipen Shah

Abstract

Introduction: Stroke is one of the most feared complications during catheter ablation of atrial fibrillation (AF). While symptomatic thromboembolic events are rare, magnetic resonance imaging (MRI) may identify asymptomatic (ie, silent) cerebral lesions (SCLs) following pulmonary vein isolation (PVI) procedures.

Methods and results: The REDUCE-TE Pilot was a prospective multicenter, single-arm observational study investigating the incidence of SCL in patients with symptomatic paroxysmal AF undergoing PVI with a novel gold-tip, externally irrigated ablation catheter. After ablation, cerebral diffusion-weighted MRI and a postablation follow-up were performed at 1 to 3 days after the ablation procedure. A neurocognitive test was done before and after ablation. The primary study endpoint was the occurrence of one or more new SCLs. Secondary study endpoints included neurocognitive status, procedural success rate, and periprocedural complications including symptomatic thromboembolic events. A total of 104 patients were enrolled (69% male, mean age: 61.5 ± 9.7 years, mean CHA2 DS 2 -VASc score: 1.7 ± 1.2). Postprocedural MRI examination was performed in 97 patients, and in nine of them (9.3%; 95% CI: 4.3-16.9%) a total of 11 SCLs were detected. Univariate analyses did not reveal any significant predictor for new SCLs. Nonsignificant trends were observed for low activated clotting time during ablation and for international normalized ratio value outside the range of 2 to 3 at ablation. There was no evidence of significant deterioration of neurocognitive function after PVI. In four patients, a pericardial tamponade was noted but all patients fully recovered during follow-up.

Conclusions: Ablation of AF using a novel gold-tip, externally irrigated ablation catheter, resulted in SCLs in approximately one out of 10 patients without a measurable effect on neurocognitive function.

Keywords: ablation; atrial fibrillation; cognitive function; gold-tip catheter; irrigated catheter; pulmonary vein isolation; silent cerebral embolism.

© 2019 The Authors. Journal of Cardiovascular Electrophysiology Published by Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Study flowchart. MRI, magnetic resonance imaging

References

    1. Gaita F, Caponi D, Pianelli M, et al. Radiofrequency catheter ablation of atrial fibrillation: A cause of silent thromboembolism?: magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation. 2010;122:1667‐1673.
    1. Schmidt B, Gunawardene M, Krieg D, et al. A prospective randomized single‐center study on the risk of asymptomatic cerebral lesions comparing irrigated radiofrequency current ablation with the cryoballoon and the laser balloon. J Cardiovasc Electrophysiol. 2013;24:869‐874.
    1. Deneke T, Jais P, Scaglione M, et al. Silent cerebral events/lesions related to atrial fibrillation ablation: a clinical review. J Cardiovasc Electrophysiol. 2015;26:455‐463.
    1. Herrera Siklódy C, Deneke T, Hocini M, et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation. J Am Coll Cardiol. 2011;58:681‐688.
    1. Haeusler KG, Koch L, Herm J, et al. 3 Tesla MRI‐detected brain lesions after pulmonary vein isolation for atrial fibrillation: results of the MACPAF study. J Cardiovasc Electrophysiol. 2013;24:14‐21.
    1. Haines DE, Stewart MT, Barka ND, et al. Microembolism and catheter ablation II: effects of cerebral microemboli injection in a canine model. Circ Arrhythmia Electrophysiol. 2013;6:23‐30.
    1. Greef YDe, Dekker L, Boersma L, et al. Low rate of asymptomatic cerebral embolism and improved procedural efficiency with the novel pulmonary vein ablation catheter GOLD: results of the PRECISION GOLD trial. Europace. 2016;18:687‐695.
    1. Spielberger CD, Gorsuch RL, Lushene RE. The State‐Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1970.
    1. Bates ME, Lemay EP. The d2 test of attention: Construct validity and extensions in scoring techniques. J Int Neuropsychol Soc. 2004;10:392‐400.
    1. Woods AT, Newell FN. Visual, haptic and cross‐modal recognition of objects and scenes. J Physiol. 2004;98:147‐159.
    1. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke‐Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220‐2241.
    1. Miyazaki S, Watanabe T, Kajiyama T, et al. Thromboembolic risks of the procedural process in second‐generation cryoballoon ablation procedures: analysis from real‐time transcranial Doppler monitoring. Circ Arrhythmia Electrophysiol. 2017;10:10.
    1. Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patient. Circulation. 2014;129:2638‐2644.
    1. Calkins H, Willems S, Gerstenfeld EP, et al. RE‐CIRCUIT investigators. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376:1627‐1636.
    1. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non‐valvular atrial fibrillation. Eur Heart J. 2015;36:1805‐1811.
    1. Doi A, Takagi M, Kakihara J, et al. Incidence and predictors of silent cerebral thromboembolic lesions after catheter ablation for atrial fibrillation in patients treated with direct oral anticoagulants. Heart Vessels. 2017;32:1227‐1235.
    1. Hummel J, Michaud G, Hoyt R, et al. Phased RF ablation in persistent atrial fibrillation. Hear Rhythm. 2014;11:202‐209.
    1. Linhart M, Liberman I, Schrickel JW, et al. Superiority of gold versus platinum irrigated tip catheter ablation of the pulmonary veins and the cavotricuspid isthmus: a randomized study comparing tip temperatures and cooling flow requirements. J Cardiovasc Electrophysiol. 2012;23:717‐721.
    1. Balázs T, Laczkó R, Bognár E, et al. Ablation time efficiency and lesion volume—in vitro comparison of 4 mm, non irrigated, gold‐ and platinum‐iridium‐tip radiofrequency ablation catheters. J Interv Card Electrophysiol. 2013;36:13‐18.
    1. Arbelo E, Brugada J, Blomström‐Lundqvist C, et al. Contemporary management of patients undergoing atrial fibrillation ablation: in‐hospital and 1‐year follow‐up findings from the ESC‐EHRA atrial fibrillation ablation long‐term registry. Eur Heart J. 2017;38:1303‐1316.
    1. Morillo CA, Verma A, Connolly SJ, et al. RAAFT‐2 Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first‐line treatment of paroxysmal atrial fibrillation (RAAFT‐2). JAMA. 2014;311:692.
    1. Medi C, Evered L, Silbert B, et al. Subtle post‐procedural cognitive dysfunction after atrial fibrillation ablation. J Am Coll Cardiol. 2013;62:531‐539.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다